Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Loyola University
Jonsson Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
University of Pittsburgh
Tarix Pharmaceuticals
Fred Hutchinson Cancer Center
Mesoblast, Ltd.